ImmunoForge Inc. receives U.S. FDA ODD for PF1801
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
SEOUL, South Korea and SILVER SPRING, Md., Oct. 29, 2021 /PRNewswire-Asianet/ -- ImmunoForge (Co-CEOs Sung-Min Ahn, Kiho Chang), a company specializing in developing new drugs for rare musculoskeletal diseases, has reported that their new drug candidate PF1801 which is in development for treatment of Duchenne Muscular Dystroph...
Authors: LATEST ASIANET NEWS RELEASES